Daiichi Sankyo
6
12M
4
0.38
2
0.33
2
- Areas of investment
Summary
Daiichi Sankyo appeared to be the Corporate Investor, which was created in 2005. The main office of represented Corporate Investor is situated in the Parsippany. The venture was found in North America in United States.
This organization was formed by Mike Rothe.
The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2012. The increased amount of exits for fund were in 2014. The usual things for fund are deals in the range of 50 - 100 millions dollars.
Among the most successful fund investment fields, there are Biotechnology, Therapeutics. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Coherus Biosciences.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Daiichi Sankyo, startups are often financed by Medpace, Helix Ventures. The meaningful sponsors for the fund in investment in the same round are Medpace, Lilly Ventures, Helix Ventures. In the next rounds fund is usually obtained by Helix Ventures, Vivo Capital, Viva Capital Advisors.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 0.38
- Follow on index
- 0.33
- Investments by industry
- Health Care (5)
- Medical (4)
- Medical Device (3)
- Pharmaceutical (2)
- Biotechnology (2) Show 4 more
- Investments by region
-
- United States (1)
- Japan (5)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Group Appearance index
- 0.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cuorips, Inc. | 07 Aug 2017 | Health Care, Medical Device, Medical | Seed | 910K | Hokkaido Prefecture, Sapporo, Japan |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.